Marktanalyse - Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016

Global Markets Direct
12.2016
136 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease — Pipeline Review, H2 2016, provides an overview of the Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline landscape.

Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 9, 4, 1, 6, 2 and 1 respectively.

Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anemia in Chronic Kidney Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Hematological Disorders)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Anemia in Chronic Kidney Disease (Renal Anemia) Overview 10

Therapeutics Development 11

Pipeline Products for Anemia in Chronic Kidney Disease (Renal Anemia) - Overview 11

Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics under Development by Companies 12

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Anemia in Chronic Kidney Disease (Renal Anemia) - Products under Development by Companies 19

Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development 22

3SBio Inc 22

Acceleron Pharma Inc 23

Aevi Genomic Medicine Inc 24

Akebia Therapeutics Inc 25

Amgen Inc 26

Bayer AG 27

Biocad 28

CCM Duopharma Biotech Bhd 29

Chong Kun Dang Pharmaceutical Corp 30

CJ HealthCare Corp 31

Daiichi Sankyo Company Ltd 32

Dong-A Socio Holdings Co Ltd 33

Dr. Reddy's Laboratories Ltd 34

FibroGen Inc 35

GlaxoSmithKline Plc 36

Intas Pharmaceuticals Ltd 37

Japan Tobacco Inc 38

JCR Pharmaceuticals Co Ltd 39

Jiangsu Hansoh Pharmaceutical Co Ltd 40

LG Life Science LTD 41

Myungmoon pharmaceutical Co Ltd 42

Panacea Biotec Ltd 43

Pfizer Inc 44

PharmaEssentia Corp 45

PhytoHealth Corp 46

Pieris Pharmaceuticals Inc 47

Reliance Life Sciences Pvt Ltd 48

Sandoz International GmbH 49

Zydus Cadila Healthcare Ltd 50

Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment 51

Assessment by Monotherapy Products 51

Assessment by Target 52

Assessment by Mechanism of Action 54

Assessment by Route of Administration 56

Assessment by Molecule Type 58

Drug Profiles 60

daprodustat - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

darbepoetin alfa - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

darbepoetin alfa - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

darbepoetin alfa - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

darbepoetin alfa - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

darbepoetin alfa - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

darbepoetin alfa - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

darbepoetin alfa - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

darbepoetin alfa - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

darbepoetin alfa - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

darbepoetin alfa - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

DS-1093 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

EPO-018B - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

epoetin alfa - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

epoetin alfa - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

epoetin zeta - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

erythropoietin - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

FG-2216 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

HSA-EPO - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

JTZ-951 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

LBDE - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

MDGN-201 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

MMP-0101 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

molidustat - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

PEG-EPO - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

Peg-EPO - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

PEG-EPO - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

pegylated erythropoietin - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

PHEP-01 - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

PRS-080 - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

Recombinant Protein for Renal Anemia - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

roxadustat - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

sotatercept - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

SSS-06 - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

SSS-17 - Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

vadadustat - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects 121

Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products 122

Anemia in Chronic Kidney Disease (Renal Anemia) - Product Development Milestones 123

Featured News & Press Releases 123

Nov 24, 2016: GSK starts phase III programme with daprodustat for anemia associated with chronic kidney disease 123

Sep 26, 2016: Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia 123

Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease 124

Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients 125

Aug 09, 2016: Kissei and JCR to Initiate a Phase III Clinical Trial of a Long-Acting Erythropoiesis-Stimulating Agent (Development Code: JR-131) 126

Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease 126

Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan 126

Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment 128

May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction 128

May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat 129

Apr 26, 2016: Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings 130

Apr 08, 2016: Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's nephrology indication 130

Mar 09, 2016: Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat 131

Feb 16, 2016: FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease 131

Jan 04, 2016: Akebia Initiates Phase 3 PRO2TECT Program 133

Appendix 135

Methodology 135

Coverage 135

Secondary Research 135

Primary Research 135

Expert Panel Validation 135

Contact Us 135

Disclaimer 136





List of Tables

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Development by Companies, H2 2016 (Contd..1) 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Comparative Analysis by Unknown Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Development by Companies, H2 2016 (Contd..2) 21

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by 3SBio Inc, H2 2016 22

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Acceleron Pharma Inc, H2 2016 23

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Aevi Genomic Medicine Inc, H2 2016 24

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Akebia Therapeutics Inc, H2 2016 25

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Amgen Inc, H2 2016 26

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Bayer AG, H2 2016 27

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Biocad, H2 2016 28

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CCM Duopharma Biotech Bhd, H2 2016 29

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 30

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CJ HealthCare Corp, H2 2016 31

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 32

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 33

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 34

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FibroGen Inc, H2 2016 35

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by GlaxoSmithKline Plc, H2 2016 36

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Intas Pharmaceuticals Ltd, H2 2016 37

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Japan Tobacco Inc, H2 2016 38

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by JCR Pharmaceuticals Co Ltd, H2 2016 39

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016 40

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by LG Life Science LTD, H2 2016 41

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Myungmoon pharmaceutical Co Ltd, H2 2016 42

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panacea Biotec Ltd, H2 2016 43

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pfizer Inc, H2 2016 44

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PharmaEssentia Corp, H2 2016 45

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PhytoHealth Corp, H2 2016 46

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pieris Pharmaceuticals Inc, H2 2016 47

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2016 48

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Sandoz International GmbH, H2 2016 49

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 50

Assessment by Monotherapy Products, H2 2016 51

Number of Products by Stage and Target, H2 2016 53

Number of Products by Stage and Mechanism of Action, H2 2016 55

Number of Products by Stage and Route of Administration, H2 2016 57

Number of Products by Stage and Molecule Type, H2 2016 59

Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H2 2016 121

Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products, H2 2016 12





List of Figures

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 51

Number of Products by Targets, H2 2016 52

Number of Products by Stage and Targets, H2 2016 52

Number of Products by Mechanism of Actions, H2 2016 54

Number of Products by Stage and Mechanism of Actions, H2 2016 54

Number of Products by Routes of Administration, H2 2016 56

Number of Products by Stage and Routes of Administration, H2 2016 56

Number of Products by Molecule Types, H2 2016 58

Number of Products by Stage and Molecule Types, H2 2016 58

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus